About Boundless Bio
Boundless Bio is a company based in San Diego (United States) founded in 2018.. Boundless Bio has raised $251.99 million across 4 funding rounds from investors including Fidelity Investments, Bayer and ARE. The company has 64 employees as of December 31, 2024. Boundless Bio offers products and services including ecDTx Therapies. Boundless Bio operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
- Headquarter San Diego, United States
- Employees 64 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Boundless Bio, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-65.36 M-32.22as on Dec 31, 2024
-
EBITDA
$-72.18 M-34.07as on Dec 31, 2024
-
Total Equity Funding
$251.99 M (USD)
in 4 rounds
-
Latest Funding Round
$100 M (USD), Series C
May 16, 2023
-
Investors
Fidelity Investments
& 20 more
-
Employee Count
64
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Boundless Bio
Boundless Bio is a publicly listed company on the NASDAQ with ticker symbol BOLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Boundless Bio
Boundless Bio offers a comprehensive portfolio of products and services, including ecDTx Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapies targeting extrachromosomal DNA in oncogene amplified cancers
Unlock access to complete
Unlock access to complete
Funding Insights of Boundless Bio
Boundless Bio has successfully raised a total of $251.99M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $100.0M
-
First Round
First Round
(19 Sep 2019)
- Investors Count 21
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series C - Boundless Bio | Valuation | Bayer , RA Capital Management | |
| Jun, 2022 | Amount | Grant - Boundless Bio | Valuation |
investors |
|
| Apr, 2021 | Amount | Series B - Boundless Bio | Valuation | Nextech Invest , RA Capital Management |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Boundless Bio
Boundless Bio has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Bayer and ARE. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sectoral Asset Management is focused on global healthcare investment.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Boundless Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Boundless Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Boundless Bio Comparisons
Competitors of Boundless Bio
Boundless Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Boundless Bio
Frequently Asked Questions about Boundless Bio
When was Boundless Bio founded?
Boundless Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Boundless Bio located?
Boundless Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Boundless Bio a funded company?
Boundless Bio is a funded company, having raised a total of $251.99M across 4 funding rounds to date. The company's 1st funding round was a Series B of $105.59M, raised on Sep 19, 2019.
How many employees does Boundless Bio have?
As of Dec 31, 2024, the latest employee count at Boundless Bio is 64.
What does Boundless Bio do?
Boundless Bio was founded in 2018 and is headquartered in San Diego, United States. Operations center on the biotechnology sector, where therapeutics are developed to address cancer through targeting extrachromosomal DNA (ecDNA). Emphasis is placed on ecDNA biology to create treatments for patients with oncogene-amplified cancers that are difficult to manage. The companys domain is boundlessbio.com.
Who are the top competitors of Boundless Bio?
Boundless Bio's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
What products or services does Boundless Bio offer?
Boundless Bio offers ecDTx Therapies.
Is Boundless Bio publicly traded?
Yes, Boundless Bio is publicly traded on NASDAQ under the ticker symbol BOLD.
Who are Boundless Bio's investors?
Boundless Bio has 21 investors. Key investors include Fidelity Investments, Bayer, ARE, Citadel, and RA Capital.
What is Boundless Bio's ticker symbol?
The ticker symbol of Boundless Bio is BOLD on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.